publication . Other literature type . Article . 2016

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.

Lijun Cao; Dongfang Li; Peng Feng; Lin Li; Guo-Fang Xue; Guanglai Li; Christian Hölscher;
  • Published: 13 Apr 2016
  • Publisher: Ovid Technologies (Wolters Kluwer Health)
  • Country: United Kingdom
Abstract
The incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are growth factors. GLP-1 mimetics are on the market as treatments for type 2 diabetes. Both GLP-1 and GIP mimetics have shown neuroprotective properties in previous studies. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in a clinical trial in Parkinson’s disease (PD) patients. Novel GLP-1/GIP dual-agonist peptides have been developed to treat diabetes. Here, we report the neuroprotective effects of a novel dual agonist (DA-JC1) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP was injected once daily (20 m...
Subjects
Medical Subject Headings: nervous systemendocrine systemhormones, hormone substitutes, and hormone antagonists
free text keywords: General Neuroscience, Neuroprotection, Incretin, Substantia nigra, Parkinson's disease, medicine.disease, medicine, Striatum, MPTP, chemistry.chemical_compound, chemistry, MPTP Poisoning, Agonist, medicine.drug_class, Endocrinology, medicine.medical_specialty, Biology, Internal medicine
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Other literature type . Article . 2016

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.

Lijun Cao; Dongfang Li; Peng Feng; Lin Li; Guo-Fang Xue; Guanglai Li; Christian Hölscher;